Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands.
Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Microbiol Spectr. 2024 Nov 5;12(11):e0114224. doi: 10.1128/spectrum.01142-24. Epub 2024 Sep 24.
Since March 2022, an increase was observed in multidrug-resistant microorganisms (MDRO), associated with the hospital transfer of Ukrainian patients. The goal was to collect phenotypic susceptibility data and assess clinical implications. Carbapenemase-producing Enterobacterales (CPE, = 96), (CPPA, = 20), and carbapenem-resistant (CRAB, = 6) from Ukrainian patients were obtained from March to December 2022 from the Dutch MDRO surveillance. Antimicrobial susceptibility testing was performed using broth microdilution (BMD) when available, fosfomycin agar dilution, disk diffusion (DD) for cefiderocol, and diverse gradient strips. All isolates were sequenced with Illumina next-generation sequencing. For meropenem, aminoglycosides, ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-relebactam, susceptibility rates were low (0%-30%), due to the high number of -positive isolates (79/122; 65%). For cefiderocol, results depended on reading with or without microcolonies, applying EUCAST or CLSI breakpoints, and whether DD or BMD was used; e.g., for , 30%-97% were susceptible. For colistin, 103/111 (93%) non-intrinsically resistant CPE/CPPA/CRAB isolates were susceptible. For most CPE, a low minimal inhibitory concentration (MIC) of <0.5 mg/L was measured for tigecycline and ceftazidime-avibactam-aztreonam. For CPPA, cefiderocol tested susceptible in 65%-100% of isolates. For CRAB, ampicillin-sulbactam MICs were ≥128 mg/L; for sulbactam-durlobactam, 1-2 mg/L. Admission in a Ukrainian hospital in the last year was a risk factor for MDRO, and majority were screening isolates (79%). There is extensive phenotypic resistance to last-resort antibiotics in MDRO from Ukrainian patients. Interpretation of cefiderocol susceptibility results depends on several variables. When treating patients recently admitted in Ukraine, suspected for Gram-negative bacterial infection, this should be taken into consideration.
Since March 2022, multidrug-resistant microorganisms associated with Ukrainian patients have been detected in national surveillance systems of several European countries. We studied the phenotypic antimicrobial susceptibility to last-resort antibiotics of multidrug-resistant microorganisms from Ukrainian patients in the Netherlands and assessed clinical implications. Our research revealed that there was extensive phenotypic resistance to last-resort antibiotics. Healthcare professionals should be aware of multidrug-resistant microorganisms when treating patients recently admitted in Ukraine, suspected for Gram-negative bacterial infection.
自 2022 年 3 月以来,与乌克兰患者的医院转院相关的多药耐药微生物(MDRO)数量有所增加。目标是收集表型药敏数据并评估临床意义。2022 年 3 月至 12 月,从荷兰 MDRO 监测中获得了 96 株产碳青霉烯酶肠杆菌科(CPE)、20 株碳青霉烯类耐药肺炎克雷伯菌(CPRA)和 6 株碳青霉烯类耐药鲍曼不动杆菌(CRAB),这些菌株均来自乌克兰患者。当可用时,使用肉汤微量稀释(BMD)进行抗生素药敏试验,使用磷霉素琼脂稀释法、头孢地尔稀释法(用于 cefiderocol)和各种梯度条进行纸片扩散(DD)试验。所有分离株均通过 Illumina 下一代测序进行测序。对于美罗培南、氨基糖苷类、头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦和亚胺培南-雷巴坦,由于 -阳性分离株(79/122;65%)数量较高,因此药敏率较低(0%-30%)。对于头孢地尔,结果取决于是否存在微菌落,采用 EUCAST 或 CLSI 折点,以及是否使用 DD 或 BMD,例如,对于 ,30%-97%的菌株敏感。对于多粘菌素,111 株非固有耐药的 CPE/CPPA/CRAB 分离株中,有 103 株(93%)敏感。对于大多数 CPE,替加环素和头孢他啶-阿维巴坦-阿扎巴坦的最小抑菌浓度(MIC)值较低,<0.5 mg/L。对于 CPPA,头孢地尔在 65%-100%的分离株中表现为敏感。对于 CRAB,氨苄西林-舒巴坦的 MIC 值≥128mg/L;对于舒巴坦-多尼培南,1-2mg/L。在过去一年中在乌克兰医院住院是 MDRO 的一个危险因素,且大多数为筛查分离株(79%)。从乌克兰患者中分离的 MDRO 对最后一线抗生素有广泛的表型耐药性。头孢地尔药敏结果的解释取决于几个变量。当治疗最近在乌克兰住院、疑似革兰氏阴性细菌感染的患者时,应考虑这一点。
自 2022 年 3 月以来,与乌克兰患者相关的多药耐药微生物已在几个欧洲国家的国家监测系统中发现。我们研究了荷兰从乌克兰患者中分离的多药耐药微生物对最后一线抗生素的表型药敏性,并评估了其临床意义。我们的研究表明,对最后一线抗生素存在广泛的表型耐药性。当治疗最近在乌克兰住院、疑似革兰氏阴性细菌感染的患者时,医护人员应注意多药耐药微生物。